Press Release
| View printer-friendly version |
| « Back |
 |
|
FibroGen Announces Investigational Anti-CTGF Therapeutic, FG-3019, Reduces Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer
|
South San Francisco, CA - June 22, 2006 FibroGen, Inc., today announced the publication of two studies demonstrating that connective tissue growth factor (CTGF) plays a causative role in pancreatic cancer and that FG-3019, the Company's fully human monoclonal antibody against CTGF, blocks tumor growth and metastases in preclinical models of pancreatic cancer. The studies were published in the May 22 issue of Molecular Cancer Therapeutics1 and the June 1 issue of Cancer Research2. The role of CTGF as the central mediator of tissue remodeling and fibrosis (persistent and excessive scarring) is well established in the scientific literature. Several recent studies also implicate CTGF in tumor progression, including tumor cell survival and metastasis, in which CTGF is a key link in the communication between tumor cells and their stroma (the area surrounding the tumor) during the desmoplastic reaction. Desmoplasia involves the formation and proliferation of fibroblasts (cells that produce fibers and structural elements found in the extracellular matrix) and of fibrous connective tissue around the growing cancer. Elevated CTGF levels have been detected in a number of late-stage cancers besides pancreatic, including breast, glioblastoma, and sarcomas. In a study led by Amato Giaccia, Ph.D., Professor of Radiation Oncology and Radiation Biology at Stanford, researchers found that CTGF expression levels were elevated in tissue sections of pancreatic tumors. The scientists also examined human pancreatic cancer cells that were engineered to express high levels of CTGF and found this modification led to increased tumor growth in mice as a result of elevated levels of cell proliferation and decreased levels of apoptosis (""programmed"" cell death, which is normally observed in diseased cells). The scientists also reported that tumor growth by the engineered cancer cells could be inhibited by blocking CTGF with FG-3019. ""These data provide the first direct evidence implicating CTGF as a causative factor in promoting the progression of pancreatic tumors and suggest that CTGF is a viable therapeutic target,"" said Dr. Giaccia. In a separate study examining the effects of blocking CTGF activity with FG-3019, researchers at Dartmouth led by Murray Korc, M.D., Professor of Pharmacology and Toxicology and Chair of Medicine, implanted human pancreatic cancer cells into the pancreas of mice and treated them with FG-3019 two weeks after implantation. At the end of the six-week study, mice treated with FG-3019 exhibited decreased tumor growth and metastasis compared to control mice. The results also demonstrated that treatment with FG-3019 attenuated tumor angiogenesis (the formation of new blood vessels necessary for tumor cell survival and growth). There were no detectable drug-related side effects, and FG-3019 was not observed to interfere with the efficacy of gemcitabine, the current standard of clinical care, in this study. ""Our findings not only provide insight into the role of CTGF in tumor growth, progression and metastasis, but also suggest that FG-3019 warrants further study as a therapy for patients with pancreatic cancer,"" said Dr. Korc. ""These studies shed light on the potentially pivotal role of CTGF in mediating the aggressive behavior of pancreatic cancer by controlling the stromal tissue remodeling process that allows tumor cells to grow and spread,"" said David Y. Liu, Ph.D., Vice President of Research at FibroGen. ""While other growth factors have been targeted by experimental treatments for pancreatic cancer, these new findings suggest that blocking the activity of CTGF with FG-3019 provides a unique way to target the disease at a crucial point. With FG-3019, we see a unique potential for preventing the metastatic spread of tumor cells by disrupting multiple pro-tumor pathways. We are therefore planning to initiate clinical studies in 2007 in patients with pancreatic cancer."" References
Pancreatic cancer is the fourth leading cause of cancer death in the United States with over 30,000 new cases diagnosed each year. The median survival is approximately six months, and the mortality rate is nearly one hundred percent within five years after diagnosis. Pancreatic cancer is a particularly dangerous cancer because of its high rate of metastasis. The current standard of care for metastatic pancreatic cancer is gemcitabine. About FG-3019 FG-3019 is an investigational fully human monoclonal antibody against CTGF. In a phase 1 study of FG-3019 in patients with idiopathic pulmonary fibrosis, FG-3019 was found safe and well tolerated. Currently, FG-3019 is the subject of a phase 1b study in diabetic patients with incipient nephropathy. In preclinical models, FG-3019 has been shown to block fibrosis in the lung, kidney, heart, liver, and intestines; reverse arterial stiffness and improve cardiac function; and decrease proteinuria while improving renal function. About FibroGen FibroGen, Inc., is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, ischemic disease, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGens proprietary cosmetic dermal filler and biomaterials supply business. For more information about FibroGen, Inc., please visit www.fibrogen.com. Contact: " |
